ublituximab + umbralisib + lenalidomide

**ublituximab + umbralisib + lenalidomide** is an investigational triple combination drug regimen consisting of three agents: ublituximab (a glycoengineered anti-CD20 monoclonal antibody), umbralisib (a dual PI3K-delta and casein kinase-1 epsilon (CK1ε) inhibitor), and lenalidomide (an immunomodulatory agent)[2][3][5]. This combination is being studied for the treatment of **relapsed or refractory chronic lymphocytic leukemia (CLL)**. Ublituximab targets the **CD20 antigen** on B lymphocytes, enhancing antibody-dependent cellular cytotoxicity. Umbralisib inhibits PI3K-delta, a kinase critical for B-cell signaling, with additional CK1ε inhibition believed to reduce immune-mediated toxicities. Lenalidomide acts by modulating immune responses and has direct antitumor effects through interference with microenvironment support and antiangiogenic activity. The regimen is designed to achieve deep and durable responses with manageable toxicity in patients with difficult-to-treat CLL[2][3][5]. No evidence was found that this specific triple combination is used as a marketed product or has a unique brand name, nor is it widely established in clinical practice as a fixed-dose combination.

Brand names

RevlimidUkoniqBriumvi

Other names

Lenalidomide, Umbralisib, and UblituximabU2-RU-2-RU 2-R